Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.
Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups. Goudemand J, et al. Among authors: claeyssens s. Blood. 2006 Jan 1;107(1):46-51. doi: 10.1182/blood-2005-04-1371. Epub 2005 Sep 15. Blood. 2006. PMID: 16166584 Free article.
Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.
Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C. Dargaud Y, et al. Among authors: claeyssens s. Haemophilia. 2016 Jan;22 Suppl 1(Suppl 1):1-24. doi: 10.1111/hae.12860. Haemophilia. 2016. PMID: 26728503 Free PMC article.
Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A.
Saultier P, Guillaume Y, Demiguel V, Berger C, Borel-Derlon A, Claeyssens S, Harroche A, Oudot C, Rafowicz A, Trossaert M, Wibaut B, Vinciguerra C, Boucekine M, Baumstarck K, Meunier S, Calvez T, Chambost H; FranceCoag PUPs / CoMETH Prophylaxis Study Group; Hemophilia Treatment Centers of Paris-Necker. Saultier P, et al. Among authors: claeyssens s. J Pediatr. 2021 Jul;234:212-219.e3. doi: 10.1016/j.jpeds.2021.02.071. Epub 2021 Mar 4. J Pediatr. 2021. PMID: 33676933 Clinical Trial.
Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: Results from a prospective observational post-marketing study.
Goudemand J, Bridey F, Claeyssens S, Itzhar-Baïkian N, Harroche A, Desprez D, Négrier C, Chamouni P, Chambost H, Henriet C, Susen S, Borel-Derlon A. Goudemand J, et al. Among authors: claeyssens s. J Thromb Haemost. 2020 Aug;18(8):1922-1933. doi: 10.1111/jth.14928. Epub 2020 Jun 25. J Thromb Haemost. 2020. PMID: 32445594 Free PMC article.
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
Rothschild C, Laurian Y, Satre EP, Borel Derlon A, Chambost H, Moreau P, Goudemand J, Parquet A, Peynet J, Vicariot M, Beurrier P, Claeyssens S, Durin A, Faradji A, Fressinaud E, Gaillard S, Guérin V, Guérois C, Pernod G, Pouzol P, Schved JF, Gazengel C. Rothschild C, et al. Among authors: claeyssens s. Thromb Haemost. 1998 Nov;80(5):779-83. Thromb Haemost. 1998. PMID: 9843171
Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.
Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeyssens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z. Négrier C, et al. Among authors: claeyssens s. Vox Sang. 2018 Feb;113(2):120-127. doi: 10.1111/vox.12624. Epub 2017 Dec 13. Vox Sang. 2018. PMID: 29238971
Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
Tardy B, Lambert T, Chamouni P, Montmartin A, Trossaert M, Claeyssens S, Berger C, Ardillon L, Gay V, Delavenne X, Harroche A, Chelle P. Tardy B, et al. Among authors: claeyssens s. Haemophilia. 2022 Jul;28(4):542-547. doi: 10.1111/hae.14560. Epub 2022 Apr 14. Haemophilia. 2022. PMID: 35420242
88 results